Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution

@article{Ovanesov2008MechanismsOA,
  title={Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution},
  author={Mikhail V Ovanesov and Mikhail A. Panteleev and Elena I. Sinauridze and Dmitry A Kireev and Olga P. Plyushch and Konstantin G. Kopylov and Elena G Lopatina and Evgueni L. Saenko and Fazoil I. Ataullakhanov},
  journal={Blood Coagulation \& Fibrinolysis},
  year={2008},
  volume={19},
  pages={743–755}
}
Supraphysiological concentrations of recombinant activated factor VII (rVIIa, NovoSeven) are used to control bleeding in hemophilia. Current experimental evidence suggests that rVIIa may increase thrombin generation via two pathways: one being tissue factor (TF)-dependent and another being activated platelet-dependent. Contribution of TF to the rVIIa action may justify different administration profiles of rVIIa. In the present study, thrombin and fibrin generation and spatial clot formation… 
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.
TLDR
The action of rFVIIa at pharmacologic doses is dominated by the TF-dependent pathway with a minor contribution from a phospholipid-dependent mechanism, and a dose-response curve is established that is useful to explain dosing strategies.
A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
TLDR
It is suggested that triggering TG by recalcification-only may be the most sensitive assay for determining the impact of bypassing agents in haemophilic plasma, and may serve as a caution surrogate safety marker in future studies.
Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients.
TLDR
The TGT clearly distinguished between ETP0 and ETP60 in the case of any coagulation activator, but ETP increasing after rVIIa infusion was significantly higher when activated with kaolin, providing increased sensitivity of this method for monitoring hemophilia therapy.
Improvement of spatial fibrin formation by the anti‐TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation
TLDR
BAX499 significantly improves spatial coagulation by inhibiting TFPI in a spatially localized manner that is different to that observed with rVIIa.
Use of Thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation
TLDR
Microparticles of different origins demonstrated qualitatively different characteristics related to coagulation activation and propagation.
Factor XI and traveling waves: the key to understanding coagulation in hemophilia?
TLDR
Hemophilia A, B and C are hereditary bleeding disorders that result from congenital deficiencies or defects of blood coagulation factors VIII (FVIII), IX (FIX) and XI (FXI), respectively, and it is established that fibrin clot is already formed when only 5–10% of thrombin is activated, which raises a major question: why throm bin, produced after the fibrIn clot formation, is important.
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
TLDR
RFVIIa and PCC partially improved laboratory parameters, but did not reverse rivaroxaban induced-bleeding and safety, respectively.
A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX.
TLDR
The life time of the erythrocyte-based form of FIXbiot in the circulation is significantly (5-10 times) prolonged compared with its free form, suggesting that this form has potential clinical applications.
Influence of temperature on spatial fibrin clot formation process in thrombodynamics assay
TLDR
The thrombodynamics assay provided additional arguments supporting the viewpoint, that the temperature lowering itself insignificantly influences the state of the plasma hemostasis system.
...
1
2
3
4
...

References

SHOWING 1-10 OF 61 REFERENCES
A possible mechanism of action of activated factor VII independent of tissue factor.
TLDR
It is speculated that this platelet-localized thrombin generation may, in part, account for the clinical efficacy of high-dose FVIIa.
Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles.
TLDR
In vivo evidence is provided that rFVIIa specifically activates platelets, either directly or as a consequence of a burst of thrombin generation that could account for its haemostatic efficacy.
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
TLDR
The data strongly indicate that the therapeutic mechanism offactor VIIa in the medical treatment of hemophiliacs with inhibitors is in large part based on overcoming the inhibitory effect of factor VII on thrombin generation.
Platelet activity of high‐dose factor VIIa is independent of tissue factor
TLDR
It is reported that factor VIIa bound weakly to activated platelets and could initiate thrombin generation in the presence of plasma concentrations of prothrombin, factor X, factor V, antithrombin III and tissue factor pathway inhibitor.
Influence of Factor VIIa and Phospholipids on Coagulation in “Acquired” Hemophilia
TLDR
The influence of rFVIIa is dependent on TF, and phospholipids substantially increase the hemostatic (or thrombotic) potential of r FVIIa/TF, which in turn improves clot stability and thrombin generation in “acquired” hemophilia B.
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
TLDR
It is shown that rFVIIa both accelerates clot formation and inhibits fibrinolysis by activation of TAFI in factor VIII-deficient plasma, however, a large variability in antifibrinoslytic potential of rF VIIa exists between patients.
Mechanism of action of high-dose factor VIIa: points of agreement and disagreement.
TLDR
Studies looking at pharmacologic levels of factor VIIa in a model system of hemophilia and the mechanisms of coagulation using tissue factor initiation and surfaces of phospholipid vesicles, isolated platelets, and platelets in whole blood are reported.
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
TLDR
The results suggest that the therapeutic efficacy of factor VIIa in the medical treatment of hemophiliacs with inhibitors is, in part, based on overcoming the factor VII inhibitory effect.
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
TLDR
The data suggest that in a cellular system high-dose FVIIa acts primarily by enhancing the rate of thrombin generation on platelet surfaces and not by overcoming inhibition by zymogen FVII of TF-dependent activation of FX.
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
TLDR
Experiments designed to elucidate the requirement for amplified factor Xa and thrombin generation in normal hemostasis show that the resistance of plasma clots to tissue plasminogen activator (tPA)- and urokinase-induced fibrinolysis is related to the extent of throm bin generation.
...
1
2
3
4
5
...